Will Manufacturing Issues Hobble Abatacept?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's decision to push back the user fee date for Bristol-Myers Squibb's rheumatoid arthritis therapy Orencia (abatacept) could have a ripple effect on the launch of the productYou may also be interested in...
Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date
Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date
Orencia Launch Anticipated By Bristol In Early 2006
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: